GlassScriptPhysician profile
Benjamin Vandersommen
NPI 1376315598
$1,565.66
in general payments reported to CMS, 2019-2025
15 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $529 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,565.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $555.09 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $268.82 | 2024-2025 | |
| Glaxosmithkline, LLC. | $161.88 | 2024-2025 | Penmenvy, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $156.18 | 2024-2025 | Veozah |
| Lilly USA, LLC | $71.69 | 2024 | Mounjaro, Jardiance |
| Exact Sciences Corporation | $59.64 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $50.56 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.84 | 2025 | |
| Amgen INC. | $45.83 | 2024-2025 | Otezla, Repatha, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.38 | 2025 | Caplyta |
| Novo Nordisk INC | $35.34 | 2024-2025 | Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $28.80 | 2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $19.76 | 2024 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.38 | 2024 | Lifevest |
| Phathom Pharmaceuticals, INC. | $9.47 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Vandersommen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.